BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes 2017;10:223-34. [PMID: 28652791 DOI: 10.2147/DMSO.S95299] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Demarsilis A, Reddy N, Boutari C, Filippaios A, Sternthal E, Katsiki N, Mantzoros C. Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism 2022;137:155332. [DOI: 10.1016/j.metabol.2022.155332] [Reference Citation Analysis]
2 Si K, Hu Y, Wang M, Apovian CM, Chavarro JE, Sun Q. Weight loss strategies, weight change, and type 2 diabetes in US health professionals: A cohort study. PLoS Med 2022;19:e1004094. [DOI: 10.1371/journal.pmed.1004094] [Reference Citation Analysis]
3 Bays HE, Lazarus E, Primack C, Fitch A. Obesity pillars roundtable: Phentermine – Past, present, and future. Obesity Pillars 2022;3:100024. [DOI: 10.1016/j.obpill.2022.100024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Guleken Z, Uzbay T. Neurobiological and neuropharmacological aspects of food addiction. Neurosci Biobehav Rev 2022;139:104760. [PMID: 35780976 DOI: 10.1016/j.neubiorev.2022.104760] [Reference Citation Analysis]
5 Mabrouk DM, El Makawy AI, Ahmed KA, Ramadan MF, Ibrahim FM. Topiramate potential neurotoxicity and mitigating role of ginger oil in mice brain. Environ Sci Pollut Res Int 2022. [PMID: 35802336 DOI: 10.1007/s11356-022-21878-4] [Reference Citation Analysis]
6 Bays HE, Fitch A, Christensen S, Burridge K, Tondt J. Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2022;2:100018. [DOI: 10.1016/j.obpill.2022.100018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Al‐bazz D, Wilding JP. Adjunctive Therapy, Including Pharmacotherapy. Clinical Obesity in Adults and Children 2022. [DOI: 10.1002/9781119695257.ch21] [Reference Citation Analysis]
8 Haddad JD, Shah SL. Medical Management of Obesity as it Affects Reflux. Foregut 2021;1:328-335. [DOI: 10.1177/26345161211069183] [Reference Citation Analysis]
9 Sankaran D, Lakshminrusimha S, Manja V. Methamphetamine: burden, mechanism and impact on pregnancy, the fetus, and newborn. J Perinatol 2021. [PMID: 34785765 DOI: 10.1038/s41372-021-01271-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Clark JE, Welch S. Comparing effectiveness of fat burners and thermogenic supplements to diet and exercise for weight loss and cardiometabolic health: Systematic review and meta-analysis. Nutr Health 2021;27:445-59. [PMID: 33427571 DOI: 10.1177/0260106020982362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Choi J, Yoon D, Park M, Joung KI, Shin JY. Topiramate-related adverse events: Pattern and signals in the Korea Adverse Event Reporting System, 2010-2017. Medicine (Baltimore) 2020;99:e22669. [PMID: 33080709 DOI: 10.1097/MD.0000000000022669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lau NKC, Tang MHY, Ng SW, Chong YK, Chen SPL, Lee HHC, Ching CK, Mak TWL. Toxicity from illegitimate slimming agents - a 10-year case series at a tertiary toxicology laboratory in Hong Kong. Clin Toxicol (Phila) 2021;59:426-32. [PMID: 32960101 DOI: 10.1080/15563650.2020.1822529] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Engeli S, May M. Gewichtsänderung als unerwünschte Arzneimittelwirkung. Adipositas - Ursachen, Folgeerkrankungen, Therapie 2020;14:133-139. [DOI: 10.1055/a-1207-8003] [Reference Citation Analysis]
14 Naveed A, Farrukh L, Sana MK, Naveed B, Randhawa FA. Pharmacological Primary Prevention of Diabetes Mellitus Type II: A Narrative Review. Cureus 2020;12:e10033. [PMID: 32999773 DOI: 10.7759/cureus.10033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S; On behalf of RSSDI-ESI Consensus Group. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. Int J Diabetes Dev Ctries 2020;40:1-122. [DOI: 10.1007/s13410-020-00819-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
16 Li Xue Z, Muslimat Kehinde A, Liuyi L, Mzee Said Abdulraman S, Abdul Nazif M, Aaron Gia K, Abdullateef Taiye M. Obesity may increase the prevalence of Parkinson’s Disease (PD) while PD may reduce obesity index in patients. J Neurosci Neurol Disord 2020;4:024-028. [DOI: 10.29328/journal.jnnd.1001030] [Reference Citation Analysis]
17 Asgary S, Soltani R, Barzegar N, Sarrafzadegan N. Evaluation on the Effects of Tamarindus Indica L. Fruit on Body Weight and Several Cardiometabolic Risk Factors in Obese and Overweight Adult Patients: A Randomized Controlled Clinical Trial. Int J Prev Med 2020;11:24. [PMID: 32175064 DOI: 10.4103/ijpvm.IJPVM_558_18] [Reference Citation Analysis]
18 Guan Z, Jacobs G, van Pelt H, Van Gerven JMA, Burggraaf J, Zhao W. PK/PD modeling of 5-hydroxytryptophan (5-HTP) challenge test with cortisol measurement in serum and saliva. Pharmacol Res Perspect 2020;8:e00574. [PMID: 32168433 DOI: 10.1002/prp2.574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Ritchey ME, Harding A, Hunter S, Peterson C, Sager PT, Kowey PR, Nguyen L, Thomas S, Cainzos-Achirica M, Rothman KJ, Andrews EB, Anthony MS. Cardiovascular Safety During and After Use of Phentermine and Topiramate. J Clin Endocrinol Metab 2019;104:513-22. [PMID: 30247575 DOI: 10.1210/jc.2018-01010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
20 Gómez-Silva M, Piñeyro-Garza E, Vargas-Zapata R, Gamino-Peña ME, León-García A, de León MB, Llerena A, León-Cachón RBR. Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial. Sci Rep 2019;9:17833. [PMID: 31780765 DOI: 10.1038/s41598-019-54436-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Seicol BJ, Bejarano S, Behnke N, Guo L. Neuromodulation of metabolic functions: from pharmaceuticals to bioelectronics to biocircuits. J Biol Eng 2019;13:67. [PMID: 31388355 DOI: 10.1186/s13036-019-0194-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
22 Chen S, Chao S, Konerman M, Zhang W, Rao H, Wu E, Lin A, Wei L, Lok AS. Survey of Nonalcoholic Fatty Liver Disease Knowledge, Nutrition, and Physical Activity Patterns Among the General Public in Beijing, China. Dig Dis Sci 2019;64:3480-8. [PMID: 31273595 DOI: 10.1007/s10620-019-05709-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Lee CJ, Kim M, An SJ. Current Treatments on Obesity. Korean J Health Promot 2019;19:171. [DOI: 10.15384/kjhp.2019.19.4.171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Bocarsly ME. Pharmacological interventions for obesity: current and future targets. Curr Addict Rep 2018;5:202-11. [PMID: 30505644 DOI: 10.1007/s40429-018-0204-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]